$TPST
Tempest Therapeutics, Inc. Stock $tpst

$tpst Overview Financials Valuation SEC Filings Company Website

2013 Q3 Form 10-Q Financial Statement

#000110465913084216 Filed on November 13, 2013

Income Statement

Concept	2013 Q3	2012 Q4	2012 Q3
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$3.660M	$1.780M	$1.530M
YoY Change	139.22%	165.67%	313.51%
% of Gross Profit
Research & Development	$3.262M	$2.430M	$1.595M
YoY Change	104.51%	215.58%	294.8%
% of Gross Profit
Depreciation & Amortization	$70.00K	$40.00K	$30.00K
YoY Change	133.33%
% of Gross Profit
Operating Expenses	$6.925M	$4.210M	$3.120M
YoY Change	121.96%	192.36%	303.1%
Operating Profit	-$6.925M		-$3.120M
YoY Change	121.96%		303.1%
Interest Expense	$30.00K	$20.00K	$0.00
YoY Change
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$6.890M	-$4.190M	-$3.120M
YoY Change	120.83%	190.97%	305.19%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$6.891M	-$4.190M	-$3.118M
YoY Change	121.01%	190.97%	302.84%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	-$86.12	-$69.83	-$104.00
COMMON SHARES
Basic Shares Outstanding	18.20M shares	14.26M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2013 Q3	2012 Q4	2012 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$49.60M	$31.40M	$35.10M
YoY Change	41.31%	597.78%
Cash & Equivalents	$21.08M	$14.78M	$35.12M
Short-Term Investments	$28.50M	$16.60M
Other Short-Term Assets	$800.0K	$600.0K	$500.0K
YoY Change	60.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$50.41M	$31.97M	$35.58M
YoY Change	41.68%	597.16%
LONG-TERM ASSETS
Property, Plant & Equipment	$730.0K	$756.0K	$654.0K
YoY Change	11.62%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$88.00K	$93.00K	$93.00K
YoY Change	-5.38%
Total Long-Term Assets	$818.0K	$849.0K	$747.0K
YoY Change	9.5%
TOTAL ASSETS
Total Short-Term Assets	$50.41M	$31.97M	$35.58M
Total Long-Term Assets	$818.0K	$849.0K	$747.0K
Total Assets	$51.23M	$32.81M	$36.33M
YoY Change	41.01%	615.68%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$791.0K	$875.0K	$1.069M
YoY Change	-26.01%	217.03%
Accrued Expenses	$1.365M	$1.211M	$845.0K
YoY Change	61.54%	203.51%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$2.156M	$2.086M	$1.914M
YoY Change	12.64%	209.04%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$65.00K	$7.000K	$0.00
YoY Change		-91.95%
Total Long-Term Liabilities	$65.00K	$7.000K	$0.00
YoY Change		-91.95%
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.156M	$2.086M	$1.914M
Total Long-Term Liabilities	$65.00K	$7.000K	$0.00
Total Liabilities	$2.221M	$2.093M	$1.914M
YoY Change	16.04%	174.67%
SHAREHOLDERS EQUITY
Retained Earnings	-$34.18M	-$16.13M	-$11.94M
YoY Change	186.2%	514.86%
Common Stock	$17.00K	$13.00K	$14.00K
YoY Change	21.43%	550.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$49.00M	$30.72M	$34.41M
YoY Change
Total Liabilities & Shareholders Equity	$51.20M	$32.81M	$36.33M
YoY Change	40.95%	615.68%

Cashflow Statement

Concept	2013 Q3	2012 Q4	2012 Q3
OPERATING ACTIVITIES
Net Income	-$6.891M	-$4.190M	-$3.118M
YoY Change	121.01%	190.97%	302.84%
Depreciation, Depletion And Amortization	$70.00K	$40.00K	$30.00K
YoY Change	133.33%
Cash From Operating Activities	-$4.190M	-$3.490M	-$2.930M
YoY Change	43.0%	232.38%	463.46%
INVESTING ACTIVITIES
Capital Expenditures	$280.0K	$150.0K	$240.0K
YoY Change	16.67%
Acquisitions
YoY Change
Other Investing Activities	-$2.490M	-$16.70M	$0.00
YoY Change
Cash From Investing Activities	-$2.760M	-$16.84M	-$250.0K
YoY Change	1004.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-160.0K	-20.00K	4.240M
YoY Change	-103.77%		-30.49%
NET CHANGE
Cash From Operating Activities	-4.190M	-3.490M	-2.930M
Cash From Investing Activities	-2.760M	-16.84M	-250.0K
Cash From Financing Activities	-160.0K	-20.00K	4.240M
Net Change In Cash	-7.110M	-20.35M	1.060M
YoY Change	-770.75%	1838.1%	-81.0%
FREE CASH FLOW
Cash From Operating Activities	-$4.190M	-$3.490M	-$2.930M
Capital Expenditures	$280.0K	$150.0K	$240.0K
Free Cash Flow	-$4.470M	-$3.640M	-$3.170M
YoY Change	41.01%	246.67%	509.62%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P3Y1M6D
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Amendment Flag AmendmentFlag	false
CY2012Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	46848000	USD
CY2012Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-6000	USD
CY2012Q4	us-gaap	Short Term Investments ShortTermInvestments	16615000	USD
CY2012Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	574000	USD
CY2012Q4	us-gaap	Assets Current AssetsCurrent	31965000	USD
CY2012Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	756000	USD
CY2012Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	93000	USD
CY2012Q4	us-gaap	Common Stock Value CommonStockValue	13000	USD
CY2013Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	21077000	USD
CY2013Q3	us-gaap	Short Term Investments ShortTermInvestments	28489000	USD
CY2013Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	841000	USD
CY2013Q3	us-gaap	Assets Current AssetsCurrent	50407000	USD
CY2013Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	730000	USD
CY2013Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	88000	USD
CY2013Q3	us-gaap	Assets Assets	51225000	USD
CY2013Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	791000	USD
CY2013Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	34000	USD
CY2013Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	17048000	shares
CY2013Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-6891000	USD
CY2013Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1365000	USD
CY2013Q3	us-gaap	Liabilities Current LiabilitiesCurrent	2156000	USD
CY2013Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	65000	USD
CY2013Q3	us-gaap	Liabilities Liabilities	2221000	USD
CY2013Q3	us-gaap	Common Stock Value CommonStockValue	17000	USD
CY2013Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	83162000	USD
CY2013Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	3000	USD
CY2013Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-34178000	USD
CY2013Q3	us-gaap	Stockholders Equity StockholdersEquity	49004000	USD
CY2013Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2012Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2013Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2012Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2013Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2013Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2012Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2013Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2012Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2013Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2012Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2013Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	18224173	shares
CY2012Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	14268068	shares
CY2013Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	17072569	shares
CY2012Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	12622919	shares
CY2013Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3262000	USD
CY2013Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3663000	USD
CY2013Q3	us-gaap	Operating Expenses OperatingExpenses	6925000	USD
CY2013Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-6925000	USD
CY2013Q3	us-gaap	Net Income Loss NetIncomeLoss	-6891000	USD
CY2013Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-6862000	USD
CY2013Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.40
CY2012Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-3118000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-18035000	USD
CY2012Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1595000	USD
CY2012Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1525000	USD
CY2012Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-3120000	USD
CY2012Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	2000	USD
CY2012Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.42
CY2012Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	7438000	shares
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-9318000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	8518000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9603000	USD
	us-gaap	Operating Expenses OperatingExpenses	18121000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-18121000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	77000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-18044000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-9318000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3892000	USD
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	15974000	USD
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	32672000	USD
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	93000	USD
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	93000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-12781000	USD
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.14
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	15779000	shares
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-34175000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	704000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1356000	USD
	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	3700000	USD
	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	3700000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	3000	USD
	us-gaap	Temporary Equity Accretion To Redemption Value TemporaryEquityAccretionToRedemptionValue	-101000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-13406000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-7672000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-26122000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	507000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5428000	USD
	us-gaap	Operating Expenses OperatingExpenses	9320000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-9320000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	2000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-9318000	USD
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.69
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	16011000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	18263000	USD
	us-gaap	Operating Expenses OperatingExpenses	34274000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-34274000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	96000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-34178000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-34279000	USD
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-4.62
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	7419000	shares
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	169000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	262000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	51000	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	409000	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	486000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	3830000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	859000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	5558000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	262000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	416000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	836000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-84000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	793000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	791000	USD
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	212000	USD
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	359000	USD
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	1431000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-797000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-30421000	USD
	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock	34992000	USD
	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock	41091000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	32488000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	4055000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	36529000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	32488000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	39047000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	77620000	USD
	us-gaap	Other Than Temporary Impairment Losses Investments Availableforsale Securities OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities	0	USD
	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	6301000	USD
	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	30578000	USD
	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	21077000	USD
CY2011Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4541000	USD
CY2012Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	35119000	USD
	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	41192000	USD
CY2013Q3	ovas	Cash Resources Sufficient To Fund Current Operating Plan CashResourcesSufficientToFundCurrentOperatingPlan	49600000	USD
	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-size:10.0pt;font-family:Times New Roman;"> <p style="MARGIN: 0in 0in 0pt;"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">Use of estimates</font></b></p> <p style="MARGIN: 0in 0in 0pt;"> </p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">These condensed consolidated financial statements are presented in conformity with U.S. generally accepted accounting principles which require management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from such estimates.</font></p> </div>
CY2013Q3	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	21077000	USD
CY2012Q4	ovas	Cash And Money Market Funds Amortized Cost CashAndMoneyMarketFundsAmortizedCost	14776000	USD
CY2012Q4	ovas	Cash And Money Market Funds Fair Value CashAndMoneyMarketFundsFairValue	14776000	USD
CY2012Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	31397000	USD
CY2012Q4	us-gaap	Availableforsale Securities Gross Unrealized Gain AvailableforsaleSecuritiesGrossUnrealizedGain	5000	USD
CY2012Q4	us-gaap	Available For Sale Securities Fair Value Disclosure AvailableForSaleSecuritiesFairValueDisclosure	31391000	USD
CY2012Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	14776000	USD
CY2012Q4	ovas	Cash Cash Equivalents And Marketable Securities Amortized Cost CashCashEquivalentsAndMarketableSecuritiesAmortizedCost	31397000	USD
CY2012Q4	us-gaap	Available For Sale Securities Gross Unrealized Losses1 AvailableForSaleSecuritiesGrossUnrealizedLosses1	11000	USD
CY2013Q3	us-gaap	Available For Sale Securities Gross Unrealized Losses1 AvailableForSaleSecuritiesGrossUnrealizedLosses1	6000	USD
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	item
	ovas	Number Of Geographic Segments NumberOfGeographicSegments	1	item
CY2013Q3	ovas	Fair Value Assets Level1 To Level2 Transfer Amount FairValueAssetsLevel1ToLevel2TransferAmount	0	USD
	ovas	Fair Value Assets Level1 To Level2 Transfer Amount FairValueAssetsLevel1ToLevel2TransferAmount	0	USD
CY2013Q3	ovas	Fair Value Assets Level2 To Level1 Transfer Amount FairValueAssetsLevel2ToLevel1TransferAmount	0	USD
	ovas	Fair Value Assets Level2 To Level1 Transfer Amount FairValueAssetsLevel2ToLevel1TransferAmount	0	USD
CY2013Q3	ovas	Fair Value Liabilities Level1 To Level2 Transfer Amount FairValueLiabilitiesLevel1ToLevel2TransferAmount	0	USD
	ovas	Fair Value Liabilities Level1 To Level2 Transfer Amount FairValueLiabilitiesLevel1ToLevel2TransferAmount	0	USD
CY2013Q3	ovas	Fair Value Liabilities Level2 To Level1 Transfer Amount FairValueLiabilitiesLevel2ToLevel1TransferAmount	0	USD
	ovas	Fair Value Liabilities Level2 To Level1 Transfer Amount FairValueLiabilitiesLevel2ToLevel1TransferAmount	0	USD
CY2013Q3	ovas	Cash And Money Market Funds Amortized Cost CashAndMoneyMarketFundsAmortizedCost	21077000	USD
CY2013Q3	ovas	Cash And Money Market Funds Fair Value CashAndMoneyMarketFundsFairValue	21077000	USD
CY2013Q3	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	49563000	USD
CY2013Q3	us-gaap	Availableforsale Securities Gross Unrealized Gain AvailableforsaleSecuritiesGrossUnrealizedGain	9000	USD
CY2012Q4	ovas	Cash Cash Equivalents And Marketable Securities Fair Value CashCashEquivalentsAndMarketableSecuritiesFairValue	31391000	USD
CY2013Q3	ovas	Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Number Of Securities AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsNumberOfSecurities	13	item
	ovas	Available For Sale Securities Continuous Unrealized Loss Position Twelve Months Or Longer Number Of Securities AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerNumberOfSecurities	0	item
CY2013Q3	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue	14700000	USD
CY2013Q3	us-gaap	Other Than Temporary Impairment Losses Investments Availableforsale Securities OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities	0	USD
CY2013Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	15900000	USD
CY2012Q3	us-gaap	Other Than Temporary Impairment Losses Investments Availableforsale Securities OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities	0	USD
	us-gaap	Other Than Temporary Impairment Losses Investments Availableforsale Securities OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities	0	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	200000	USD
CY2013Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	200000	USD
	ovas	Development Stage Enterprise Product Revenues DevelopmentStageEnterpriseProductRevenues	0	USD
CY2013Q3	us-gaap	Preferred Stock Value PreferredStockValue		USD
CY2012Q4	us-gaap	Preferred Stock Value PreferredStockValue		USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	9000	USD
CY2013Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	29000	USD
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	364000	USD
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	364000	USD
CY2013Q3	ovas	Additional Share Based Compensation Expense With Respect To Modification Of Awards AdditionalShareBasedCompensationExpenseWithRespectToModificationOfAwards	200000	USD
	ovas	Additional Share Based Compensation Expense With Respect To Modification Of Awards AdditionalShareBasedCompensationExpenseWithRespectToModificationOfAwards	200000	USD

Files In Submission

Name	View Source	Status
0001104659-13-084216-index-headers.html	Edgar Link	pending
0001104659-13-084216-index.html	Edgar Link	pending
0001104659-13-084216.txt	Edgar Link	pending
0001104659-13-084216-xbrl.zip	Edgar Link	pending
a13-19542_110q.htm	Edgar Link	pending
a13-19542_1ex10d1.htm	Edgar Link	pending
a13-19542_1ex10d2.htm	Edgar Link	pending
a13-19542_1ex10d3.htm	Edgar Link	pending
a13-19542_1ex10d4.htm	Edgar Link	pending
a13-19542_1ex10d5.htm	Edgar Link	pending
a13-19542_1ex31d1.htm	Edgar Link	pending
a13-19542_1ex31d2.htm	Edgar Link	pending
a13-19542_1ex32d1.htm	Edgar Link	pending
a13-19542_1ex32d2.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
g195421kgi001.jpg	Edgar Link	pending
g195421kii001.jpg	Edgar Link	pending
ovas-20130930.xml	Edgar Link	completed
ovas-20130930.xsd	Edgar Link	pending
ovas-20130930_cal.xml	Edgar Link	unprocessable
ovas-20130930_def.xml	Edgar Link	unprocessable
ovas-20130930_lab.xml	Edgar Link	unprocessable
ovas-20130930_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$TPST
Tempest Therapeutics, Inc. Stock $tpst

2013 Q3 Form 10-Q Financial Statement

#000110465913084216 Filed on November 13, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TPST Tempest Therapeutics, Inc. Stock $tpst

2013 Q3 Form 10-Q Financial Statement

#000110465913084216 Filed on November 13, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TPST
Tempest Therapeutics, Inc. Stock $tpst